Investigating how gut bacteria affect drug effectiveness in tuberculosis and diabetes patients
Official title: Gut Microbiome and Pharmacokinetic Variability in Tuberculosis and Diabetes
Funded at Rutgers Biomedical and Health Sciences · NIH-10893634 · Data updated 2026-11-12
This study is looking at how the bacteria in your gut might affect how well tuberculosis medications work, especially for people with and without type 2 diabetes, to help create better, personalized treatments for everyone.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project start | July 8, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $202,217 |
| NIH project number | 5K23AI159396-04 |
| Project ID | NIH-10893634 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with active tuberculosis and type 2 diabetes mellitus.
✕Less likely to help
Patients without tuberculosis or diabetes, or those with other unrelated health conditions, may not benefit from this research.
What this research studies
This research aims to understand how the gut microbiome influences the effectiveness of tuberculosis (TB) medications in patients with and without type 2 diabetes mellitus (DM). By analyzing stool samples and drug absorption rates, the study will explore the relationship between gut bacteria diversity and drug pharmacokinetics. Patients will be involved in a prospective observational trial that examines how diabetes affects drug bioavailability and treatment outcomes in TB. The findings could lead to personalized treatment strategies for TB patients based on their gut microbiome composition.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment outcomes for tuberculosis patients, particularly those with diabetes, by optimizing drug therapies based on individual gut microbiome profiles.
How similar studies have gone: Other research has shown promising results in understanding the role of the gut microbiome in drug metabolism, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Rutgers Biomedical and Health Sciences
Newark, United States Active
Researchers
- Principal investigator: Narayanan, Navaneeth — Rutgers Biomedical and Health Sciences
- Study coordinator: Narayanan, Navaneeth
Related research
Other NIH-funded projects on the same topics.
-
Understanding how diabetes affects tuberculosis and the body’s defense against it
A patient-focused look at how having diabetes changes the way the immune system fights tuberculosis and how this might influence treatment in people with both conditions.
-
Serological and gut virome profiling in type 2 diabetes
A study will map how people with type 2 diabetes respond to gut microbes and their viruses, to see how this interaction relates to diabetes.
-
TB infection and heart health: how latent TB may raise diabetes and heart disease risk
This project looks at whether having latent tuberculosis infection raises the chances of developing diabetes and cardiovascular disease, and what epigenetic clues might explain this link.
-
How early arsenic exposure affects children's gut bacteria and diabetes risk
Finding out if arsenic exposure in early life changes gut bacteria and increases the chance of developing diabetes in children.
-
Investigating the gut bacteria in lean and obese youth with type 1 diabetes and how metformin affects them
This study is looking at how the bacteria in the gut might be different in kids with type 1 diabetes who are either obese or lean, and it also wants to see if the diabetes medicine metformin can help improve their gut health and insulin use, all to find ways to help these young people feel better.
-
How stress-related high blood sugar affects tuberculosis treatment and diabetes risk
This study is looking at how stress-related high blood sugar affects the treatment of tuberculosis (TB) and whether it increases the chances of developing diabetes afterward, specifically for patients in places like Georgia where both conditions are common.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.